IQVIA Holdings Inc (IQV)

This article provides a detailed peer comparison for IQVIA Holdings Inc. (IQV) against other biotechnology companies like Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna, and Revolution Medicines. It presents key financial metrics including market cap, revenue, net profit, profitability ratios, growth ratios, valuation ratios, solvency ratios, and operating efficiency ratios, allowing investors to analyze IQV's performance relative to its competitors. The data covers income statements, liabilities, assets, cashflow, and various financial ratios for each company.

IQVIA has received multiple industry awards for its AI and technology innovations in life sciences and healthcare, recognized for solutions that enhance decision-making, streamline workflows, and optimize clinical trials. These awards, including a Gold Stevie for Technical Innovation and an AI Breakthrough Award, highlight the company's commitment to responsible AI use and its ability to deliver significant operational efficiencies and improved patient outcomes. Notably, an AI-enabled tool for identifying misdiagnosed diabetes patients reduced screening burden by 99.5%.

IQVIA Holdings (IQV) shares have recently rallied by 21.7%, driven by investor interest in its data assets, AI technology, and share repurchase program, leading to a 3-month return of 56.64%. Despite this run-up, the stock is considered modestly undervalued at $259.42 compared to a narrative fair value of $275.17, with analysts projecting annual revenue growth of 6.3% and an increase in profit margins to 9.9% over the next three years. However, the company faces potential risks such as CRO pricing pressure and high leverage.

IQVIA Holdings (IQV) stock reached a new 52-week high in late August 2026, driven by strong second-quarter earnings, an upgraded full-year guidance, and increased institutional investment. The company reported EPS of $3.15 and revenue of $4.37 billion, surpassing analyst expectations, and subsequently raised its fiscal 2026 EPS guidance. This performance, coupled with significant institutional ownership, supports the stock's premium valuation despite concerns about liquidity and the absence of a dividend.

IQVIA (IQV) stock has outperformed its industry and the S&P 500, with strong projected earnings and revenue growth. The company benefits from extensive data assets, robust technology infrastructure, solid operating cash flow, and a shareholder-friendly share repurchase program. However, it faces risks such as client budget-driven pricing pressure, absence of dividends, and weak liquidity.